Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMS04: Doxorubicin + Trabectedin in Leiomyosarcoma
NCT02997358Phase 3Completed
- Sponsor
- Gustave Roussy
- Start
- Jan 2017
- Primary completion
- Jul 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trabectedin in leiomyosarcoma (LMS), sponsored by Gustave Roussy. Started Jan 2017; status: completed.
02
Drugs
trabectedin
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT02997358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02997358.